Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | ALPI | P09923 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | XIAP | P98170 | 1/20 | 1.00 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.69 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.69 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.69 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.59 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Phenylalanine SCHEMBL1331077 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL1332173 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL288606 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL1331829 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL8835931 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL23159186 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL1331777 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL2785094 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL1330932 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL1331205 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10732182-B2 | Method for predicting cancer sensitivity | EUTROPICS PHARMACEUTICALS, INC. (US) | 2020-08-04 | — | — | US | claimed |
| US-11656230-B2 | Method for predicting cancer sensitivity | EUTROPICS PHARMACEUTICALS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| WO-2022015974-A2 | SUBSTITUTED 4-(3-AMINOPROP-1-YL)AMINOQUINOLINE ANALOGS AS MODULATORS OF MELANOMA-ASSOCIATED ANTIGEN 11 UBIQUITIN LIGASE | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2022-01-20 | — | — | WO | disclosed |
| WO-2021054425-A1 | BLOOD SERUM SPECIMEN INSPECTION DEVICE, AND METHOD FOR INSPECTING BLOOD SERUM SPECIMEN | 伊藤 寛晃 | 2021-03-25 | — | — | WO | disclosed |
| US-20200393468-A1 | METHOD FOR PREDICTING CANCER SENSITIVITY | EUTROPICS PHARMACEUTICALS, INC. | 2020-12-17 | — | — | US | disclosed |
| CN-108997575-B | Polyethylene glycol-b-polytyrosine-lipoic acid copolymer, polypeptide micelle and preparation method and application thereof | 苏州大学 | 2020-12-15 | — | — | CN | disclosed |
| CN-107998453-B | Surface-modified acellular matrix and modification method thereof | 中山大学附属第一医院 | 2020-09-25 | — | — | CN | disclosed |
| US-10732182-B2 | Method for predicting cancer sensitivity | EUTROPICS PHARMACEUTICALS, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20160178634-A1 | METHOD FOR PREDICTING CANCER SENSITIVITY | EUTROPICS PHARMACEUTICALS, INC. | 2016-06-23 | — | — | US | disclosed |
| WO-2015017788-A1 | METHOD FOR PREDICTING CANCER SENSITIVITY | EUTROPICS PHARMACEUTICALS, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-20080146632-A1 | Fc Receptor Modulating Compounds and Compositions | TRILLIUM THERAPEUTICS, INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-7332631-B2 | These compounds typically have a core lipophilic group, substituted with a group rich in pi -electrons, preferably having a delocalised pi -electron system; typically include at least one acidic group having a pi -electron system; Autoimmune diseases | TRILLIUM THERAPEUTICS INC. (CA) | 2008-02-19 | — | — | US | disclosed |
| US-20060264484-A1 | Fc receptor modulating compounds and compositions | THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD (AU) | 2006-11-23 | — | — | US | disclosed |
| US-20060057144-A1 | Fc receptor modulators and uses thereof | ILEXUS PTY LIMITED (AU) | 2006-03-16 | — | — | US | disclosed |
| US-6835753-B2 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | ILEXUS PTY LIMITED (AU) | 2004-12-28 | — | — | US | disclosed |
| EP-1109545-A4 | Fc RECEPTOR MODULATORS AND USES THEREOF | ILEXUS PTY LTD (AU) | 2004-11-10 | — | — | EP | disclosed |
| US-20020061844-A1 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | ILEXUS PTY LIMITED | 2002-05-23 | — | — | US | disclosed |
| US-6355683-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE | ILEXUS PTY LIMITED (AU) | 2002-03-12 | — | — | US | disclosed |
| EP-1109545-A1 | Fc RECEPTOR MODULATORS AND USES THEREOF | ILEXUS PTY LTD (AU) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000015214-A1 | Fc RECEPTOR MODULATORS AND USES THEREOF | ILEXUS PTY LIMITED (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146632-A1 | Fc Receptor Modulating Compounds and Compositions | FCGR1A, FCGR2A, FCGR3B | SLC7A5 1202/4885PTGS1 828/4885ALPI 2982/4885 |
| US-20060264484-A1 | Fc receptor modulating compounds and compositions | FCGR1A, FCGR2A, FCGR3B | SLC7A5 1337/4885PTGS1 705/4885ALPI 3835/4885 |
| US-20020061844-A1 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | FCGR2A, FCGR1A, FCER2 | SLC7A5 176/4885PTGS1 1835/4885ALPI 2611/4885 |
| US-20060057144-A1 | Fc receptor modulators and uses thereof | FCGR1A, FCER2, FCGR2A | SLC7A5 4227/4885PTGS1 745/4885ALPI 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.